19
Clinical Trials associated with TQB-2618评估TQB2618注射液联合派安普利单抗注射液与盐酸安罗替尼胶囊一线治疗晚期肝细胞癌的有效性和安全性Ib期临床研究
[Translation] Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and anlotinib hydrochloride capsules as first-line treatment for advanced hepatocellular carcinoma
主要目的:评价TQB2618注射液联合派安普利单抗与安罗替尼在晚期肝细胞癌患者中的有效性。
次要目的:评价TQB2618注射液联合派安普利单抗与安罗替尼在晚期肝细胞癌患者中的安全性;评价TQB2618注射液、派安普利单抗的免疫原性特征。
探索性目的:与疗效、机制、安全性相关生物标志物研究。
[Translation] Primary objective: To evaluate the efficacy of TQB2618 injection combined with pembrolizumab and anlotinib in patients with advanced hepatocellular carcinoma.
Secondary objective: To evaluate the safety of TQB2618 injection combined with pembrolizumab and anlotinib in patients with advanced hepatocellular carcinoma; to evaluate the immunogenicity characteristics of TQB2618 injection and pembrolizumab.
Exploratory objective: To study biomarkers related to efficacy, mechanism, and safety.
A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
This is a Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection as monotherapy and a combination regimen (with Penpulimab injection ± Anlotinib hydrochloride capsules) in the treatment of advanced colorectal cancer. 75 participants will be enrolled in the study. Objective response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 is the primary endpoint.
评估 TQB2618 注射液单药及联合方案(派安普利单抗±安罗替尼)四线及后线治疗晚期结直肠癌的有效性和安全性 Ib 期临床研究
[Translation] Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection alone and in combination with penpulimab ± anlotinib in the fourth-line and later-line treatment of advanced colorectal cancer
评价TQB2618注射液(TIM-3单抗)单药及联合方案(派安普利单抗±安罗替尼)在晚期结直肠癌患者中的有效性与安全性
[Translation] To evaluate the efficacy and safety of TQB2618 injection (TIM-3 monoclonal antibody) alone and in combination (pembrolizumab ± anlotinib) in patients with advanced colorectal cancer
100 Clinical Results associated with TQB-2618
100 Translational Medicine associated with TQB-2618
100 Patents (Medical) associated with TQB-2618
100 Deals associated with TQB-2618